Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fadolmidine

Drug Profile

Fadolmidine

Alternative Names: Fado; MPV 2426; Radolmidine

Latest Information Update: 28 Oct 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Orion
  • Developer Orion; Recro Pharma
  • Class Analgesics; Imidazoles; Indans; Small molecules
  • Mechanism of Action Alpha 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Postoperative pain
  • No development reported Neuropathic pain

Most Recent Events

  • 28 Oct 2018 No recent reports of development identified for phase-I development in Neuropathic-pain in USA (Topical)
  • 19 Oct 2016 fadolmidine is still in phase I trial for Neuropathic-pain in USA (Topical) (Recro Pharma pipeline, October 2016)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Neuropathic-pain in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top